Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  NeoStem Inc    NBS

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

NeoStem Inc : NeoStem Announces Closing of Public Offering of Common Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 03:46pm CET

NeoStem Announces Closing of Public Offering of Common Stock May 3 2013

New York, May 3, 2013 -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the closing of a previously announced underwritten public offering of 23,000,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 3,000,000 shares, offered at a price to the public of $0.50 per share. The gross proceeds to the Company were $11,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Aegis Capital Corp. acted as sole book-running manager of the offering.

This offering is being made pursuant to a shelf registration statement that the Company previously filed with the Securities and Exchange Commission (SEC), and which became effective on October 3, 2012. Electronic copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from the SEC's website at http://www.sec.gov or from Aegis Capital Corp, 810 7th Avenue, 18th Floor, New York, NY 10019 or via telephone at 212-813-1010 or email: prospectus@aegiscap.com.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Company's securities. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization ("CDMO") providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

For more information, please visit: www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts for cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEOSTEM INC
12/05 Caladrius Biosciences to Present at Upcoming December Conferences
11/23 CALADRIUS BIOSCIENCES : Subsidiary, PCT, Earns FACT Re-Accreditation for its Cel..
11/22 CALADRIUS BIOSCIENCES : Subsidiary, PCT, Earns FACT Re-Accreditation for its Cel..
11/07 CALADRIUS BIOSCIENCES, INC. : Results of Operations and Financial Condition, Reg..
11/07 CALADRIUS BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
11/07 Caladrius Biosciences Reports 2016 Third Quarter Financial Results
11/02 CALADRIUS BIOSCIENCES TO HOST 2016 T : 00 pm Eastern Time
11/01 CALADRIUS BIOSCIENCES : Begins Enrollment of Second Cohort of Phase 2 Trial of C..
10/31 CALADRIUS BIOSCIENCES : Begins Enrollment of Second Cohort of Phase 2 Trial of C..
10/27 Caladrius Biosciences to Present at Upcoming November Conferences
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Financials ($)
Sales 2016 32,2 M
EBIT 2016 -33,3 M
Net income 2016 -35,1 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 0,96x
Capi. / Sales 2017 0,86x
Capitalization 30,7 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 11,2 $
Spread / Average Target 197%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David J. Mazzo Chief Executive Officer & Director
Steven S. Myers Chairman
Joseph Talamo Chief Financial Officer & Senior Vice President
Douglas W. Losordo Chief Medical Officer & SVP-Regulatory Affairs
Robert A. Preti Director, Chief Technical Officer & Senior VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOSTEM INC31
INCYTE CORPORATION-5.98%19 208
QUINTILES IMS HOLDINGS..12.04%18 939
CELLTRION, INC.--.--%9 932
LONZA GROUP AG9.44%9 350
SEATTLE GENETICS, INC.45.03%9 214
More Results